Eli Lilly partners US groups on TB drug R&D
US drug major Eli Lilly has announced a public-private partnership with several US organizations to research and develop drugs against tuberculosis, according to the Seattle Times. The decision was made public at the Seattle-based Pacific Health Summit.
Lilly added that the new initiative would be based at Seattle's Infectious Disease Research Institute and would not be designed to generate profits for the drug firm. The drug major will provide $3.0 million annually over the next five years to the project. Partners include: Afya world Medicines; the Global Alliance for TB Drug Development; Julibant Biosys; Merck & Co; the Seattle Biomedical Research Institute; and the locally-based University of Washington's Department of Global Health.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze